Skip to main content
OpenTrials
Completed

NCT Number: NCT00225485

Study Evaluating Effexor XR in Elderly Patients With Major Depression.

Phase III study evaluating Effexor XR in elderly patients with major depression.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Ichikawa, Chiba, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with major depression based on DSM-IV-TR
  • Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" of HAM-D at baseline

Exclusion criteria

  • Patients with schizophrenia or any other psychotic disorder
  • Patients with history or presence of bipolar disorder

Treatment and study plan

Effexor XR

Drug

Primary outcomes

  1. Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy

Secondary outcomes

  1. Difference of total score of HAM-D17 between baseline and final-on-therapy

  2. Remission rate of HAM-D17 at the final-on-therapy

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

Phase III Study of Effexor XR for the Treatment of Elderly Patients With Depression

Important dates

Study start
2003
First posted
Sep 23, 2005
Registry last updated
May 28, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.